________________________________________________________________________________________________________________________________

(C) Wolf G Kroner 2013 - Michael SchulzCorporate Compliance
Training the paper tiger to purr, show its teeth, or jump on

October 2013. Preventing unlawful behaviour or enforcing compliance is a learning process, in particular with moving targets. Michael Schulz, CFO of Bayer CropScience and Compliance Officer answers straight questions. What are the lessons from uncovering a corruption case at Bayer Brasil Lda? How many cases is he dealing with per year? How are fraudulous suppliers detected? How are scientists prevented to leak R&D secrets? Or: Is the company’s compliance policy a paper tiger?

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 5 pages
- Includes Bayer's handling of corruption case in Brazil

Full Company License enquire here

Back to section

Related Editorial Articles

AstraZeneca / MedImmune Trigger Public Investments into Brazil's Translational Healthcare
A public-private partnership becomes a building block of São Paulo State’s industrial diversification strategy of State

OECD: Brazil needs to improve greater integrity in public service

FAO: Major shifts expected in operations
José Graziano da Silva, new Director-General, answers probing questions

No Mercy with Violators of Corporate Compliance
Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director (until June 2013) on dealing with corrupt practices, for example in Brazil, India, or other countries

Roche Ethiopia: Build-up of an emerging market

TALEs, Zinc Fingers, or Meganucleases
A Practice View from Crop Research and Breeding by Johan Botterman, Head of Product Research Bayer CropScience

Industrial Bioscience: Solutions marketing never dreamt of…
David Nicholson, CSO of Bayer CropScience on hidden potentials, revaluation of IP assets, and substantial changes in R&D